StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research note issued to investors on Sunday morning. The firm issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Price Performance
Acorda Therapeutics stock opened at $0.66 on Friday. The company has a current ratio of 0.33, a quick ratio of 0.26 and a debt-to-equity ratio of 3.07. The company has a market capitalization of $819,640.00, a PE ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a 12 month low of $0.61 and a 12 month high of $24.20. The stock has a 50-day moving average price of $11.13 and a two-hundred day moving average price of $12.16.
Acorda Therapeutics Company Profile
Further Reading
- Five stocks we like better than Acorda Therapeutics
- What is Forex and How Does it Work?
- 3 Companies Buying Back Cheap Stock Lately
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Roku Trims Losses and Raises Guidance, But Market Isn’t Convinced
- What is a Death Cross in Stocks?
- Kimberly-Clark Proves the Best Offense is a Good Defensive Stock
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.